Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. XTLB
XTLB logo

XTLB

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

XTLB News

XTL Biopharmaceuticals Faces Nasdaq Delisting Risk

Feb 27 2026seekingalpha

XTL Biopharmaceuticals Faces Nasdaq Delisting Risk

Feb 27 2026Newsfilter

XTL Biopharmaceuticals Faces Nasdaq Delisting Risk with $47,000 Equity Deficit

Jan 23 2026seekingalpha

Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes

Jan 16 2026NASDAQ.COM

Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%

Jan 14 2026Benzinga

XTL Biopharmaceuticals Acquires 85% of NeuroNOS for $1M and Up to $32.5M in Milestones

Jan 13 2026stocktwits

Beyond Air (XAIR) Sells 85% of NeuroNOS for Up to $32.5 Million

Jan 13 2026Benzinga

XTL Biopharmaceuticals Acquires 85% of NeuroNOS to Target Autism Treatment Market

Jan 13 2026Globenewswire

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Targeting Autism Therapeutics Market

Jan 13 2026NASDAQ.COM

XTL Acquires 85% of NeuroNOS for $32.5 Million to Target Autism Treatment

Jan 13 2026Globenewswire

Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%

Jan 02 2026Benzinga

XTL Biopharmaceuticals Faces Nasdaq Delisting Risk, Must Regain Compliance in 180 Days

Dec 26 2025Newsfilter

XTL Biopharmaceuticals Fails to Meet Nasdaq Minimum Bid Price Requirement

Dec 24 2025Globenewswire

Vision Marine Technologies Stock Rises Over 10%; Check Out 20 Stocks Making Moves in Premarket Trading

Dec 01 2025Benzinga

What’s Driving the Rise of Pharmaceutical Stocks XBIO, UPC, XTLB, and ACXP Today?

Oct 08 2025TipRanks

Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

Jul 07 2025Benzinga